Plus: new Eversense sales suspended; high fat & protein diets and insulin; new pump tech; more
Can't see the images? View as webpage.
Facebook
Twitter
LinkedIn
To ensure that you never miss an issue, please whitelist us.

March 28, 2020: Issue #1035

TOP STORIES - Diabetes News & Research

Comparisons of GLP-1 Agonists

Trending High Fat and Protein Diets May Need Insulin Dose Adjustments

New Technology In Insulin Pumps Will Shape The Future 
Letter from the Editor

A couple of weeks ago I shared some of the success my wife was having with the Control-IQ technology on her T-slim pump. Last week one of my former interns, who is a professor at Nova Southeastern College of Pharmacy, reached out to me to share her success as well.

Tandem, the maker of the T-slim pump and Control-IQ, is not just resting on their laurels and this week our intern Mit Suthar, PharmD. Candidate, LECOM College of Pharmacy, has a nice overview of what they have for our patients going forward.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief


Doctor's Option
lab test products include rapid tests and CLIA certified fingerstick lab tests.

Rapid tests offer immediate test results to provide doctors with point of care test results in as little as 90 seconds.

Fingerstick lab tests provide CLIA certified lab accurate results. Each fingerstick lab test collection kit comes with a prepaid postage return envelope and everything you need to obtain and collect your fingerstick blood sample in a 510K FDA approved device.

Fingerstick lab tests are great for people who want to monitor their blood sugar, cholesterol, lipids and other important bio-markers at home or on the go.

Visit Doctor's Option

Newsflash: Senseonics Suspends New 90-Day Eversense Sales


Senseonics effectively ceased operations, per an 8-K filed on Thursday. The Company is, effective immediately, suspending commercial sales in the United States of its 90-day Eversense continuous glucose monitoring (“CGM”) system to new patients and physician practices. The company stated that it intends to continue distributing the 90-day Eversense system to patients currently using the system for the foreseeable future.

TOP STORIES - Diabetes News and Research

Comparisons of GLP-1 Agonists
Which GLP-1RA provides better benefits?
READ MORE
Trending High Fat and Protein Diets May Need Insulin Dose Adjustments
Do meals with high fat or high protein content allow for the prescribed insulin dose to balance glucose levels in a patient with type 1 diabetes? 
READ MORE
New Technology In Insulin Pumps Will Shape The Future 
A breakthrough in software for insulin pumps approved by the FDA. 
READ MORE

Did You Know? New Study Shows That Gender Can Affect How We React to Fasting


Fasting may be beneficial for health, potentially reducing susceptibility to diseases, including diabetes and high blood pressure. But we don’t yet know which type is best and for whom. Fasts can vary in length and time of day, and this can also determine how easily people can stick to them. According to research published in The Journal of Physiology , in response to short, six-hour fasts in mice, female mice put on more liver fat than males, but also seemed to be better at using it up. Researchers at the University of Sydney fasted mice for six hours each night over four weeks. They chose the night because this is the active phase of the mice, mimicking daytime fasting in humans. In some aspects, males and females responded similarly to the short daily fasting, with both showing changes in food intake, lean mass, and glucose metabolism. However, these parameters changed to different extents, with males eating more, growing bigger, and having larger livers. The key difference between the sexes was found in the liver with fat storage and usage in the liver, differing in males and females. After four weeks of short daily fasting, female mice had accumulated more liver fat compared to males, but also showed increased potential for using those stores – better at storing lipids, but even better at using them. This suggests fasting is may be more beneficial to women, specifically in terms of liver health, which impacts the likelihood of developing diabetes, high blood pressure, and kidney disease. However, more research is needed to find out whether this applies to humans. A significant finding from this study is that in preclinical studies, it is essential to include both sexes.

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Antonio Bess, Pharm D Candidate, Florida Agricultural & Mechanical University School of Pharmacy

Mit Suthar, PharmD. Candidate, LECOM School of Pharmacy 

Chardae Whitner PharmD Candidate L|E|C|O|M Bradenton School of Pharmacy

Alayna Marteal Wyre, Pharm. D. Candidate, South College School of Pharmacy 

 About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com
Facebook
Twitter
LinkedIn
©2020 HIPER, LLC. All rights reserved.

This email was sent by eHealthcare Solutions on behalf of:
Diabetes In Control
810 Bear Tavern Rd, Suite 102
Ewing, NJ, 08628, United States


DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe